Roche Licenses Ionis' Antisense HD Therapy Following Groundbreaking Trial

Roche exercised its option to license Ionis Pharmaceuticals’ Huntington’s disease (HD) antisense drug candidate, IONIS-HTT RX , on the back of what have been called “groundbreaking” results from a placebo-controlled Phase I/IIa dose escalation study. Roche is paying $45 million up front for the license, and will shoulder all continued development and commercialization activities for IONIS-HTT RX for the HD indication. Ionis will be eligible to receive undisclosed mil